{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:09:42Z","timestamp":1787850582587,"version":"build-2784847793"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital, Taiwan","doi-asserted-by":"publisher","award":["XPRPG3H0011~5"],"award-info":[{"award-number":["XPRPG3H0011~5"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital, Taiwan","doi-asserted-by":"publisher","award":["DOH-102-TD-C-111-006"],"award-info":[{"award-number":["DOH-102-TD-C-111-006"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital, Taiwan","doi-asserted-by":"publisher","award":["MOST 110-2314-B-182-018"],"award-info":[{"award-number":["MOST 110-2314-B-182-018"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The clinical presentations of essential thrombocythemia (ET) may be quite similar to early\/prefibrotic primary myelofibrosis (pre-PMF), especially in pre-PMF presenting with thrombocytosis (pre\u2013PMF-T), but may be associated with a different outcome. It is very important to distinguish these two entities. The aim of this study was to address the clinical and prognostic relevance of distinguishing pre\u2013PMF-T from ET.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All patients, including 258 with ET and 105 with pre\u2013PMF-T, received JAK2V617F, MPL (exon 10), and CALR (exon 9) mutation analysis and allele burden measurement for JAK2V617F and CALR mutants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients with pre\u2013PMF-T had an older age and higher leukocyte and platelet counts but lower hemoglobin levels than patients with ET. Patients with pre\u2013PMF-T had a shorter overall, leukemia-free, and thrombosis-free survival compared with patients with ET. Patients with ET had a higher rate of cerebral ischemic stroke, whereas patients with pre\u2013PMF-T tended to have splanchnic vein thrombosis. The frequencies of JAK2V617F, CALR, and MPL mutations and CALR allele burden were no different, but JAK2V617F allele burden was significantly higher in pre\u2013PMF-T. Patients with pre\u2013PMF-T with the JAK2V617F mutation had an inferior overall survival and thrombosis-free survival, whereas the status of driver gene mutations did not influence the outcomes of patients with ET.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>ET and pre\u2013PMF-T were two distinct disease entities and exhibited different clinical phenotype, genotype, and outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ajcp\/aqac173","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T21:32:12Z","timestamp":1677706332000},"page":"474-483","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early\/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan"],"prefix":"10.1093","volume":"159","author":[{"given":"Ming-Chung","family":"Kuo","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Chang Gung University , Taoyuan , Taiwan"},{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Yu","family":"Chuang","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"},{"name":"Department of Pathology, Chang Gung Memorial Hospital at Linkou , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Chang Gung University , Taoyuan , Taiwan"},{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Huei","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hou","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Chang Gung University , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Liang","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Chang Gung University , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Wei","family":"Ou","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Chang Gung University , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Shin","family":"Hung","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Chang Gung University , Taoyuan , Taiwan"},{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Yu","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Chang Gung University , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Jung","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Chang Gung University , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Nan","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Chang Gung University , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Yung","family":"Shih","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Chang Gung University , Taoyuan , Taiwan"},{"name":"College of Medicine, Chang Gung University , Taoyuan , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"2023050207544611400_CIT0001","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood."},{"key":"2023050207544611400_CIT0002","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0300-2977(98)00143-0","article-title":"Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis","volume":"54","author":"Michiels","year":"1999","journal-title":"Neth J Med."},{"key":"2023050207544611400_CIT0003","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood."},{"key":"2023050207544611400_CIT0004","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"2023050207544611400_CIT0005","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","article-title":"Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes","volume":"111","author":"Wilkins","year":"2008","journal-title":"Blood."},{"key":"2023050207544611400_CIT0006","first-page":"93","article-title":"Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features\u2014a clinicopathological study on 272 patients","volume":"18","author":"Thiele","year":"2003","journal-title":"Histol Histopathol."},{"key":"2023050207544611400_CIT0007","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1080\/10428190600678975","article-title":"Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology","volume":"47","author":"Gianelli","year":"2006","journal-title":"Leuk Lymphoma."},{"key":"2023050207544611400_CIT0008","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1055\/s-2006-939433","article-title":"Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders","volume":"32","author":"Thiele","year":"2006","journal-title":"Semin Thromb Hemost."},{"key":"2023050207544611400_CIT0009","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","article-title":"Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification","volume":"117","author":"Thiele","year":"2011","journal-title":"Blood."},{"key":"2023050207544611400_CIT0010","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol."},{"key":"2023050207544611400_CIT0011","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","article-title":"Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis","volume":"129","author":"Guglielmelli","year":"2017","journal-title":"Blood."},{"key":"2023050207544611400_CIT0012","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s12185-018-2495-2","article-title":"Early\/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia","volume":"108","author":"Kamiunten","year":"2018","journal-title":"Int J Hematol."},{"key":"2023050207544611400_CIT0013","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/ejh.13236","article-title":"Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan","volume":"102","author":"Edahiro","year":"2019","journal-title":"Eur J Haematol."},{"key":"2023050207544611400_CIT0014","first-page":"1200","article-title":"The international consensus classification of myeloid neoplasms and acute leukemias: myeloproliferative neoplasms","author":"Thiele","year":"2022","journal-title":"Am J Hematol."},{"key":"2023050207544611400_CIT0015","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia."},{"key":"2023050207544611400_CIT0016","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1182\/blood.V83.3.744.744","article-title":"Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay","volume":"83","author":"Shih","year":"1994","journal-title":"Blood."},{"key":"2023050207544611400_CIT0017","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica."},{"key":"2023050207544611400_CIT0018","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.leukres.2012.09.012","article-title":"Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure","volume":"37","author":"Shih","year":"2013","journal-title":"Leuk Res."},{"key":"2023050207544611400_CIT0019","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/jclinpath-2017-204829","article-title":"The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis","volume":"71","author":"Kuo","year":"2018","journal-title":"J Clin Pathol."},{"key":"2023050207544611400_CIT0020","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2013.219","article-title":"Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet\/MPN&MPNr-EuroNet (COST action BM0902) study","volume":"27","author":"Jovanovic","year":"2013","journal-title":"Leukemia."},{"key":"2023050207544611400_CIT0021","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood."},{"key":"2023050207544611400_CIT0022","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med."},{"key":"2023050207544611400_CIT0023","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood."},{"key":"2023050207544611400_CIT0024","doi-asserted-by":"crossref","first-page":"101735","DOI":"10.18632\/oncotarget.21594","article-title":"Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria","volume":"8","author":"Rumi","year":"2017","journal-title":"Oncotarget."},{"key":"2023050207544611400_CIT0025","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ajh.24788","article-title":"Pre-fibrotic\/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: the impact of minor clinical diagnostic criteria on the outcome of the disease","volume":"92","author":"Jeryczynski","year":"2017","journal-title":"Am J Hematol."},{"key":"2023050207544611400_CIT0026","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/leu.2015.87","article-title":"Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis","volume":"29","author":"Palandri","year":"2015","journal-title":"Leukemia."},{"key":"2023050207544611400_CIT0027","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.leukres.2017.12.005","article-title":"Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms","volume":"65","author":"Gango","year":"2018","journal-title":"Leuk Res."},{"key":"2023050207544611400_CIT0028","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12185-018-2421-7","article-title":"Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms","volume":"107","author":"Misawa","year":"2018","journal-title":"Int J Hematol."},{"key":"2023050207544611400_CIT0029","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.exphem.2009.07.005","article-title":"JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis","volume":"37","author":"Hussein","year":"2009","journal-title":"Exp Hematol."},{"key":"2023050207544611400_CIT0030","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.leukres.2015.02.006","article-title":"Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations","volume":"39","author":"Li","year":"2015","journal-title":"Leuk Res."},{"key":"2023050207544611400_CIT0031","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13000-015-0269-1","article-title":"Thrombosis in essential thrombocytemia and early\/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis","volume":"10","author":"Rupoli","year":"2015","journal-title":"Diagn Pathol."},{"key":"2023050207544611400_CIT0032","doi-asserted-by":"crossref","first-page":"e35631","DOI":"10.1371\/journal.pone.0035631","article-title":"Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis","volume":"7","author":"Barosi","year":"2012","journal-title":"PLoS One."},{"key":"2023050207544611400_CIT0033","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.3324\/haematol.2014.115113","article-title":"JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms","volume":"100","author":"Shirane","year":"2015","journal-title":"Haematologica."},{"key":"2023050207544611400_CIT0034","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood."},{"key":"2023050207544611400_CIT0035","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood."},{"key":"2023050207544611400_CIT0036","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood."},{"key":"2023050207544611400_CIT0037","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/159\/5\/474\/50149890\/aqac173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/159\/5\/474\/50149890\/aqac173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T16:43:17Z","timestamp":1701535397000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/159\/5\/474\/7066994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3,1]]},"published-print":{"date-parts":[[2023,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqac173","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,3,1]]}}}